Landlocked developing countries (LLDCs) vs Nepal: Percentage of bloodstream infection due to Escherichia coli resistant
Landlocked developing countries (LLDCs)
74.2%
in 2022
Nepal
77.1%
in 2022
Landlocked developing countries (LLDCs) rank
3rd
Nepal rank
5th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Landlocked developing countries (LLDCs)
- Nepal
How they compare
Nepal currently reports 77.1% against 74.2% in Landlocked developing countries (LLDCs), a difference of 2.9%.
Across all 5 years both countries report, Nepal has been ahead every year.
Landlocked developing countries (LLDCs) ranks 3rd and Nepal ranks 5th of 16 groups.
Nepal has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Landlocked developing countries (LLDCs) | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 39.4% | 71.3% | 31.9% | Nepal |
| 2020s | 73.7% | 76.8% | 3.1% | Nepal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Landlocked developing countries (LLDCs) or Nepal?
- Nepal, at 77.1% against 74.2% in Landlocked developing countries (LLDCs) as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Landlocked developing countries (LLDCs) and Nepal?
- 2.9%, with Nepal ahead.
- How many years of comparable data are there for Landlocked developing countries (LLDCs) and Nepal?
- 5 years are reported by both, from 2018 to 2022.
- How do Landlocked developing countries (LLDCs) and Nepal rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Landlocked developing countries (LLDCs) ranks 3rd and Nepal ranks 5th of 16 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.